What is HPV Nine-valent Vaccine?
HPV nine-valent vaccine is a vaccine for preventing cervical cancer among women. We know that cervical cancer is a malignant tumor caused by human papillomavirus (HPV) infection, which is extremely harmful. By injecting the HPV nine-valent vaccine, it can effectively prevent HPV infection, thus achieving the purpose of preventing cervical cancer. Before vaccination, it is necessary to understand the target population for this vaccine.
HPV nine-valent vaccine is used to prevent cervical cancer caused by HPV infection, which can prevent more than 90% of cervical cancer cases. On April 28, 2018, the National Medical Products Administration conditionally approved the listing of HPV nine-valent vaccine for cervical cancer prevention in China. Vaccination is a primary prevention measure, while screening is a secondary prevention measure, both of which are equally important. Therefore, cervical cancer screening measures should not be neglected after vaccination.
1. The clinical trials supporting the listing of this vaccine included women aged 16 to 26 years old. During this age group, both the vaccine's clinical research data abroad and the protective effect against persistent infection among East Asian populations suggest that its benefits outweigh the risks.
2. The probability of sexual behavior among young girls aged 9 to 15 years old in China is very low. For those aged 9 to 15 years old, only immune bridging trials have been conducted, and the clinical research data for East Asian Chinese populations in this trial is limited.
3. Women over 26 years old are highly likely to have a history of virus exposure and infection, and there is no evidence yet that this vaccine has a protective effect on exposed populations in this age group.
